Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.
Antimicrob Agents Chemother
; 58(1): 610-3, 2014.
Article
em En
| MEDLINE
| ID: mdl-24189264
ABSTRACT
Letermovir is a novel antiviral compound currently in clinical development for the prevention of human cytomegalovirus (HCMV) infections. In contrast to all currently approved anti-HCMV drugs that target the viral DNA polymerase, letermovir acts via a distinct mode of action involving the viral terminase subunit pUL56. To extend our understanding of potential letermovir resistance mechanisms, we used marker transfer to characterize mutations identified in letermovir-resistant HCMV variants that were selected in cell culture.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Quinazolinas
/
Citomegalovirus
/
Acetatos
Limite:
Humans
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article